Global cervical care Target markets include resource-limited regions with high cervical cancer burden, presenting a clear opportunity to position OncoGenesis as a cost-effective, easy-to-use screening solution that can be deployed where traditional labs are scarce.

Home self-collection iPap self-collection device enables at-home specimen collection, creating potential sales channels with public health programs, clinics, and telehealth providers seeking patient-friendly, scalable screening options.

Lab to POC rollout CerMark biomarker test planned from laboratory-based to point-of-care deployment offers a staged sales narrative to lab partnerships first, followed by adoption in clinics and mobile health units.

Strategic partnerships Past collaboration with Quanterix indicates a pathway for biomarker testing partnerships and co-development deals, suggesting opportunities to leverage diagnostic tech alliances to accelerate market access.

Leadership momentum New CEO appointment signals strategic executive focus and potential for renewed fundraising and go-to-market initiatives, which can attract investor-led partnerships and grant opportunities to advance distribution.